AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine

Agreement for Plendil in China reinforces AstraZeneca’s focus on innovative medicines.

Under the terms of the agreement, CMS will pay AstraZeneca $310 million for the license to sell Plendil in China. AstraZeneca will maintain a significant, long-term interest in the future value derived from Plendil sales in China and will manufacture and supply the medicine to CMS. AstraZeneca will retain the global rights to Plendil outside China. The transaction does not include the transfer of any AstraZeneca employees or facilities.

Mark Mallon, Executive Vice President, International at AstraZeneca, said: “This commercial collaboration supports our strategy of working with a local partner to maximise the value from our medicines in China, our second largest market globally. The agreement ensures widespread patient access to an established medicine and continued long-term revenues, while focusing our resources on commercialising innovative new medicines from our pipeline across our main therapy areas.”

Mr Lam Kong, Chairman and CEO at China Medical System Holdings Ltd said: “We are pleased to be entering into this agreement with AstraZeneca. Plendil, while a mature brand in AstraZeneca’s portfolio, represents a significant commercial opportunity in China, supported by our long track record in the market, our nationwide coverage and expertise.”

The licensing agreement for Plendil will close at signing and revenue from the agreement will be reported as Externalisation Revenue in AstraZeneca’s financial statements. The agreement does not impact AstraZeneca’s financial guidance for 2016.

AstraZeneca has also entered into an agreement with CMS and its associated company, Tibet Rhodiola Pharmaceutical Holding Co., for the divestment of the global rights to Imdur outside the US. Imdur is a mature medicine for the prevention of angina in patients with heart disease; its global sales outside the US were $57 million in 2015. Under the terms of this agreement, AstraZeneca will receive $190 million for the rights to Imdur in all markets outside the US. The divestment is expected to close in the second quarter of 2016 and income from the agreement will be reported as Core Other Operating Income. The agreement does not impact AstraZeneca’s financial guidance for 2016.